EGF受体Ⅲ型突变体在肿瘤治疗中的研究进展

Current Research on EGFRvⅢ in Cancer Therapy

EGFRⅢ型变异体 (或EGFRvⅢ )是一种新型的肿瘤特异性靶点。EGFRvⅢ是正常分子经过遗传学重排成为肿瘤特异性靶点的最好例证。由于仅在肿瘤细胞中发现EGFRvⅢ ,可以应用它设计靶向性药物选择性治疗肿瘤 ,而不影响正常细胞 ,避免传统治疗中所见的副作用。以表达EGFRvⅢ的细胞为靶点的治疗方式有三种 :1 )作为毒性抗体或修饰病毒的直接靶点 ,2 )利用EGFRvⅢmRNA的特异性核酶或EGFRvⅢ及其下游信号传导分子的特异性抑制剂进行治疗 ,3)利用EGFRvⅢ触发免疫反应。概括介绍了肿瘤特异性标记物EGFRvⅢ在肿瘤治疗中的研究进展。

A mutant EGFR(EGFR classⅢ variant,or so-called EGFR vⅢ) is a new,tumor-specific target.EGFRvⅢ is an excellent example of a normal molecule that has undergone genetic rearrangement to provide a truly tumor-specific target.Because EGFRvⅢ is only found on cancer cells,while the normal tissues are spared and possible side effects seen with traditional treatments avoided.In principle,EGFRvⅢ-expressing cells can be targeted in three different ways:1) as a direct target for toxic antibodies or modified viruses,2) the function of the EGFRvⅢ can be targeted by ribozymes specific for EGFRvⅢ mRNA and specific inhibitors of the downstream signalling molecules,or 3) EGFRvⅢ can be used to trigger an immunological response.This review summarized current research in cancer therapy on the tumor-specific marker EGFRvⅢ.;